237 related articles for article (PubMed ID: 35821619)
41. Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk.
Emberton M; Zinner N; Michel MC; Gittelman M; Chung MK; Madersbacher S
BJU Int; 2007 Aug; 100(2):249-53. PubMed ID: 17617135
[TBL] [Abstract][Full Text] [Related]
42. Effects of Steroidal Antiandrogen or 5-alpha-reductase Inhibitor on Prostate Tissue Hormone Content.
Shibata Y; Arai S; Miyazawa Y; Shuto T; Nomura M; Sekine Y; Koike H; Matsui H; Ito K; Suzuki K
Prostate; 2017 May; 77(6):672-680. PubMed ID: 28145028
[TBL] [Abstract][Full Text] [Related]
43. Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?
Silva J; Silva CM; Cruz F
Curr Opin Urol; 2014 Jan; 24(1):21-8. PubMed ID: 24231531
[TBL] [Abstract][Full Text] [Related]
44. Genetic variants in 5p13.2 and 7q21.1 are associated with treatment for benign prostatic hyperplasia with the α-adrenergic receptor antagonist.
Qian X; Xu D; Liu H; Lin X; Yu Y; Kang J; Sheng X; Xu J; Zheng S; Xu D; Qi J
Aging Male; 2017 Dec; 20(4):250-256. PubMed ID: 28787260
[TBL] [Abstract][Full Text] [Related]
45. Progression of lower urinary tract symptoms after discontinuation of 1 medication from 2-year combined alpha-blocker and 5-alpha-reductase inhibitor therapy for benign prostatic hyperplasia in men--a randomized multicenter study.
Lin VC; Liao CH; Kuo HC
Urology; 2014 Feb; 83(2):416-21. PubMed ID: 24332123
[TBL] [Abstract][Full Text] [Related]
46. Lower urinary tract symptoms/benign prostatic hyperplasia: maintaining symptom control and reducing complications.
O'Leary MP
Urology; 2003 Sep; 62(3 Suppl 1):15-23. PubMed ID: 12957196
[TBL] [Abstract][Full Text] [Related]
47. Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer.
van der Sluis TM; Meuleman EJ; van Moorselaar RJ; Bui HN; Blankenstein MA; Heijboer AC; Vis AN
BJU Int; 2012 Jan; 109(2):183-8. PubMed ID: 21992404
[TBL] [Abstract][Full Text] [Related]
48. Changes in dihydrotestosterone metabolism and the development of benign prostatic hyperplasia in the aging beagle.
Isaacs JT
J Steroid Biochem; 1983 Jun; 18(6):749-57. PubMed ID: 6191128
[TBL] [Abstract][Full Text] [Related]
49. Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms.
Jhang JF; Jiang YH; Kuo HC
Int J Clin Pract; 2013 Dec; 67(12):1327-33. PubMed ID: 24246211
[TBL] [Abstract][Full Text] [Related]
50. 5-ARI induces autophagy of prostate epithelial cells through suppressing IGF-1 expression in prostate fibroblasts.
Yang BY; Jiang CY; Dai CY; Zhao RZ; Wang XJ; Zhu YP; Qian YX; Yin FL; Fu XY; Jing YF; Han BM; Xia SJ; Ruan Y
Cell Prolif; 2019 May; 52(3):e12590. PubMed ID: 30883989
[TBL] [Abstract][Full Text] [Related]
51. Clinical effects of discontinuing 5-alpha reductase inhibitor in patients with benign prostatic hyperplasia.
Kim W; Jung JH; Kang TW; Song JM; Chung HC
Korean J Urol; 2014 Jan; 55(1):52-6. PubMed ID: 24466398
[TBL] [Abstract][Full Text] [Related]
52. Yohimbine hydrochloride inhibits benign prostatic hyperplasia by downregulating steroid 5α-reductase type 2.
Zhao Y; Zhang Y; Li Y; Yang M; Yuan J; Cao Y; Xu L; Ma X; Lin S; An J; Wang S
Eur J Pharmacol; 2021 Oct; 908():174334. PubMed ID: 34265299
[TBL] [Abstract][Full Text] [Related]
53. Ageratum conyzoides L. inhibits 5-alpha-reductase gene expression in human prostate cells and reduces symptoms of benign prostatic hypertrophy in otherwise healthy men in a double blind randomized placebo controlled clinical study.
Detering M; Steels E; Koyyalamudi SR; Allifranchini E; Bocchietto E; Vitetta L
Biofactors; 2017 Nov; 43(6):789-800. PubMed ID: 29048765
[TBL] [Abstract][Full Text] [Related]
54. Drug adherence and drug-related problems in pharmacotherapy for lower urinary tract symptoms related to benign prostatic hyperplasia.
Zabkowski T; Saracyn M
J Physiol Pharmacol; 2018 Aug; 69(4):. PubMed ID: 30552307
[TBL] [Abstract][Full Text] [Related]
55. [Guide dedicated to general practitioner for the management of lower urinary tract symptoms related to benign prostatic hyperplasia].
Descazeaud A; Barry Delongchamps N; Cornu JN; Azzouzi AR; Buchon D; Benchikh A; Coloby P; Dumonceau O; Fourmarier M; Haillot O; Lebdai S; Mathieu R; Misrai V; Saussine C; de La Taille A; Robert G;
Prog Urol; 2015 Jun; 25(7):404-12. PubMed ID: 25841758
[TBL] [Abstract][Full Text] [Related]
56. 5alpha-reductase activity in the prostate.
Steers WD
Urology; 2001 Dec; 58(6 Suppl 1):17-24; discussion 24. PubMed ID: 11750244
[TBL] [Abstract][Full Text] [Related]
57. [Benign prostatic hyperplasia--the outcome of age-induced alteration of androgen-estrogen balance?].
Weisser H; Krieg M
Urologe A; 1997 Jan; 36(1):3-9. PubMed ID: 9123678
[TBL] [Abstract][Full Text] [Related]
58. Benign Prostatic Hyperplasia.
Langan RC
Prim Care; 2019 Jun; 46(2):223-232. PubMed ID: 31030823
[TBL] [Abstract][Full Text] [Related]
59. The Impact of Combination Therapy with a-Blockers and 5ARIs on the Progression of BPH.
Sountoulides P; Gravas S
Curr Drug Targets; 2015; 16(11):1172-9. PubMed ID: 25706255
[TBL] [Abstract][Full Text] [Related]
60. Pao Pereira Extract Attenuates Testosterone-Induced Benign Prostatic Hyperplasia in Rats by inhibiting 5α-Reductase.
Liu J; Fang T; Li M; Song Y; Li J; Xue Z; Li J; Bu D; Liu W; Zeng Q; Zhang Y; Yun S; Huang R; Yan J
Sci Rep; 2019 Dec; 9(1):19703. PubMed ID: 31873149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
